Business Context and Reporting Period
Daré Bioscience, Inc. (DARE) filed this Form 8-K on April 29, 2024, reporting the entry into material definitive agreements with XOMA (US) LLC. The company is a Delaware corporation focused on women's health, with principal executive offices in San Diego, CA.
Key Financial Metrics and Transaction Details
This filing details a royalty purchase transaction rather than standard operating financial results. Key financial terms include:
- Upfront Proceeds: XOMA paid Daré $22.0 million on April 29, 2024.
- Contingent Payments: If XOMA receives total payments exceeding $88.0 million, Daré will receive $11.0 million for each successive $22.0 million received by XOMA.
- Assets Sold:
- 100% of royalties and milestones from the Organon License Agreement for XACIATO (clindamycin phosphate) vaginal gel 2% (net of third-party obligations).
- 25% of a potential future $20.0 million payment from Bayer regarding Ovaprene.
- Synthetic royalties of 4.0% on future net sales of Ovaprene and 2.0% on Sildenafil Cream (reducible to 2.5% and 1.25% respectively if XOMA's total receipts exceed $110.0 million).
The filing text does not provide current revenue, profit, cash flow, margins, or total debt figures for the company outside of this specific transaction.
Material Changes and Agreements
The primary material change is the monetization of future royalty streams to improve immediate liquidity. Specific contractual impacts include:
- Debt Repayment Option: XOMA may, at its sole discretion, repay and retire Daré's obligations under its existing royalty interest financing agreement with United in Endeavour, LLC ("UiE"). If XOMA does so, UiE payments will no longer be deducted from net royalties.
- Financing Restrictions: Daré cannot elect to receive additional funding from UiE without XOMA's prior written consent.
- Covenants: The agreements restrict Daré's ability to incur indebtedness or liens related to the sold receivables and certain product assets, though out-licensing capabilities remain unrestricted.
Outlook, Risks, and Contingencies
Management commentary is limited to the announcement of the transaction. Key contingencies and risks include:
- Future Revenue Participation: Daré retains a "Revenue Participation Right" contingent on the commercial success of Ovaprene and Sildenafil Cream, as well as the performance of XACIATO.
- Security Interest: Daré granted XOMA a security interest in certain product assets related to Ovaprene and Sildenafil Cream.
- Regulatory and Clinical Risk: The Bayer milestone payment is contingent on Bayer's election to make the license effective following the completion of a pivotal clinical trial for Ovaprene.
Investor Verification Checklist
- Verify the exact terms of the UiE Agreement repayment and how it impacts Daré's existing debt load.
- Confirm the status of the pivotal clinical trial for Ovaprene to assess the likelihood of the Bayer milestone payment.
- Review the upcoming Form 10-Q (for the quarter ending June 30, 2024) for the full text of the Agreements and any redacted confidential provisions.
- Monitor XACIATO sales performance to determine if the $88.0 million threshold for contingent payments will be met.